Twist Bioscience Corporation Common Stock

Day range

$136.19 – $147.62

Open

$139.45

Prev close

$139.92

Volume

795.43K

Market cap

$9.28B

Shares out

62.71M

P/E

—

P/S

21.48

P/B

20.81

P/FCF

—

ROE

-30.7%

ROA

-20.3%

Debt/Equity

0.03

Div yield

0.00%

As of Oct 23, 2026

• Underwriting agreementAug 5, 2026

  On August 4, 2026, Twist Bioscience Corporation (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC, William Blair & Company, L.L.C., Leerink Partners LLC, and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (collectively, the "Underwriters"), pursuant to which the Company agreed to issue and sell 3,125,000 shares of its common stock to the Underwriters (the "Offering").

• Licensing agreementFeb 17, 2026

  The Company will issue up to 324,558 shares of Common Stock to Invenra Inc. and pay $5 million in cash in consideration for a license agreement with Invenra and the transfer of certain technology from Invenra.

• Preliminary resultsJan 12, 2026

  On January 12, 2026, Twist Bioscience Corporation (the "Company") issued a press release announcing its preliminary, unaudited revenue results for the first quarter ended December 31, 2025.

• Executive compensation changeAug 6, 2025

  In connection with her service as a director, Ms. Shineman Blake will receive the Company's standard non-employee director cash and equity compensation, which includes (i) the $50,000 annual cash retainer for her service as a director, (ii) the $10,000 annual retainer for her service as a member of the Audit Committee of the Board, (iii) an initial equity award of restricted stock units with a grant date fair value of $395,000, and (iv) an annual grant of restricted stock units with a grant date value equal to $240,000 at the next annual meeting of stockholders.

• Licensing agreementMay 5, 2025

  On May 2, 2025, Twist and Purchaser entered into an MES Software License Agreement, pursuant to which Twist licensed to Purchaser the MES Software, subject to the terms and conditions set forth therein.

• DNAGinkgo Bioworks Holdings, Inc.+0.73%
• TXG10x Genomics, Inc. Class A Common Stock+2.45%

Days to cover

3.8

Short interest

10.57M

Avg volume

2.76M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
  positiveZacks Investment Research· Oct 26, 2026
• Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
  neutralThe Motley Fool· Oct 22, 2026
• Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera
  positiveGlobeNewswire Inc.· Oct 12, 2026
• Global Oligonucleotide Synthesis Reagents Market Size, Share, and Forecast, 2026-2033 | Therapeutics Demand Fuels 11.9% CAGR and USD 1.75 Billion Opportunity
  positiveGlobeNewswire Inc.· Oct 5, 2026
• Why Twist Bioscience Stock Skyrocketed This Week
  positiveThe Motley Fool· Sep 18, 2026